P-81 Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1–positive metastatic colorectal cancer (mCRC)

T. Kim, J. Taieb, M. Passhak,T. Kim, S. Kim, R. Geva,E. Hofsli, G. Perl,S. Yalcin, A. Hubert, B. Somer, Z. Wong, A. Wang, P. Leconte, D. Fogelman, V. Heinemann

Annals of Oncology（2022）

引用 0|浏览1